Ke Xu

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Combination Therapy

Health Information

Top Venues

Expert review of clinical pharmacology

Expert review of anticancer therapy

Bioscience reports

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke Xu
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis. Expert review of anticancer therapy (2023)
Yan Feng, Pengcheng Li, Fang Yang, Ke Xu
Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. Medicine 101 (51) (2023)
Yan Feng, Pengcheng Li, Fang Yang, Ke Xu
Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. Medicine 101 (51) (2023)
Ke Xu, Tianlei Wang, Shenbin Pan, Jie He
The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis. Expert review of clinical pharmacology (2023)
Yan Feng, Pengcheng Li, Fang Yang, Ke Xu
Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. Medicine 101 (51) (2023)
Bo Liu, Tingting Fu, Ping He, Chengyou Du, Ke Xu
Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Bioscience reports 41 (7) (2022)
Ke Xu, Tao Liu, Jie Zhang, Yangang Zhou, Fang Yang, Tao Ren
The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis. International journal of clinical oncology 25 (9) (2020)